Ultragenyx Pharmaceutical Inc. buy The Goldman Sachs Group, Inc.
Start price
06.06.24
/
50%
€40.80
Target price
06.06.25
€61.55
Performance (%)
-21.08%
End price
07.06.25
€32.20
Summary
This prediction ended on 07.06.25 with a price of €32.20. The prediction for Ultragenyx Pharmaceutical Inc. disappointed with a performance of -21.08%. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 2.083% | 2.083% | -51.000% |
| iShares Core DAX® | -0,38 % | 2,61 % | 11,34 % |
| iShares Nasdaq 100 | -0,41 % | -2,00 % | 5,35 % |
| iShares Nikkei 225® | 1,84 % | 9,39 % | 33,53 % |
| iShares S&P 500 | -0,71 % | -0,48 % | 2,51 % |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was upgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "buy" rating. They now have a $67.00 price target on the stock, up previously from $56.00.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von The_Goldman_Sachs_Gr gewählte maximale Laufzeit wurde überschritten
Stopped prediction by The_Goldman_Sachs_Gr for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€46.20
02.08.24
02.08.24
€69.62
02.08.25
02.08.25
-46.75%
03.08.25
03.08.25
